<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00502528</url>
  </required_header>
  <id_info>
    <org_study_id>BQ123AMI12/06</org_study_id>
    <nct_id>NCT00502528</nct_id>
  </id_info>
  <brief_title>Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction</brief_title>
  <official_title>Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background and Objective: Acute coronary syndrome is characterized by compromised blood flow
      at the epicardial and microvascular levels. The aim of the present study is to investigate
      the effect of ET-receptor blockade by BQ-123 on myocardial perfusion and infarct size as an
      adjunct to PCI-reperfusion therapy in patients with STEMI.

      Patients are randomized to receive periinterventional intravenous BQ-123 or placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background and Objective: Acute coronary syndrome is characterized by compromised blood flow
      at the epicardial and microvascular levels. We have previously shown that thrombectomy in
      ST-elevation myocardial infarction (STEMI) accelerates ST-segment resolution, possibly by
      preventing distal embolization. Therefore, we analyzed the vasoconstrictor concentration of
      acute coronary thrombi, and found high concentrations of endothelin (ET) which correlated
      with the magnitude of ST-segment resolution within one hour of percutaneous coronary
      intervention (PCI). Furthermore, ET-receptor blockade by tezosentan significantly repressed
      vasoconstriction in an in-vitro model using porcine coronary artery rings incubated with
      coronary thrombus homogenates extracted from STEMI patients.

      The aim of the present study is to investigate the effect of ET-receptor blockade by BQ-123
      on myocardial perfusion and infarct size as an adjunct to PCI-reperfusion therapy in patients
      with STEMI.

      Methods: Fifty eligible patients will be randomized to receive periinterventional intravenous
      BQ-123 or placebo. The primary endpoint of the study will be microvascular function evaluated
      by cardiac magnetic resonance tomography.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2007</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Myocardial perfusion determined by CMR</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Final infarct size determined by CMR</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular function determined by CMR</measure>
    <time_frame>3 days/ 6 months (6-months Remodeling-substudy)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma NT-BNP</measure>
    <time_frame>30 days/ 6 months (6-months substudy)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Enzymatic infarct size (CK levels)</measure>
    <time_frame>3 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG ST-segment resolution</measure>
    <time_frame>1 hour</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers of inflammation</measure>
    <time_frame>24 hours/ 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac events (MACE) (cardiovascular death, re-hospitalization for unstable angina and AMI, hospitalization for worsening heart failure)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver function</measure>
    <time_frame>24hours/ 3 days/ 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event free survival</measure>
    <time_frame>6 months (6-months substudy)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Holter ECG</measure>
    <time_frame>3 days / 30 days (EP-substudy)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">57</enrollment>
  <condition>ST-Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BQ-123</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Peri-interventional</description>
    <arm_group_label>1</arm_group_label>
    <other_name>sodium salt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BQ-123</intervention_name>
    <description>Peri-interventional</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Cyclo(-D-Trp-D-Asp-Pro-D-Val-Leu) sodium salt</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  STEMI patients (defined as: Evidence of ischemic chest pain for &gt;30 minutes within &lt;12
             hours and new ST-segment elevation for â‰¥2 mm in two or more contiguous
             electrocardiographic leads or in case of a true posterior infarction reciprocal
             ST-segment depressions in in V1 and V2 &gt;1mm and/or elevated serum creatine
             phosphokinase or twofold elevation of troponin-T), aged 18 years and above, who
             undergo primary percutaneous revascularization (PCI) and have confirmed initial TIMI 0
             or 1 in the infarct related coronary artery.

        Exclusion Criteria:

          -  Significant liver disease

          -  Thrombolytic therapy

          -  History of prior myocardial infarction

          -  Current atrial fibrillation

          -  History of congestive heart failure

          -  History of migraine headache

          -  Significant valvular heart disease, primary myocardial disease

          -  Cardiogenic shock (sRR &lt;90mmHg or need for inotropic support)

          -  Child-bearing potential

          -  Inability to read, understand and sign the informed consent

          -  Life expectancy &lt;3y

          -  Prior organ transplantation

          -  Medication with konazoles, ritonavir, rifampicin and sulfonyl-urea derivatives

          -  Participation in another clinical study

          -  Metal implants contraindicating CMR
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irene M Lang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <state>Vienna-Austria</state>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <results_reference>
    <citation>Adlbrecht C, Andreas M, Redwan B, Distelmaier K, Mascherbauer J, Kaider A, Wolzt M, Tilea IA, Neunteufl T, Delle-Karth G, Maurer G, Lang IM. Systemic endothelin receptor blockade in ST-segment elevation acute coronary syndrome protects the microvasculature: a randomised pilot study. EuroIntervention. 2012 Apr;7(12):1386-95. doi: 10.4244/EIJV7I12A218.</citation>
    <PMID>22522549</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2007</study_first_submitted>
  <study_first_submitted_qc>July 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 17, 2007</study_first_posted>
  <last_update_submitted>April 27, 2013</last_update_submitted>
  <last_update_submitted_qc>April 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Irene Lang</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Infarction</keyword>
  <keyword>Endothelin</keyword>
  <keyword>Perfusion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>cyclo(Trp-Asp-Pro-Val-Leu)</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

